Share

FDA Approves Spinal Cord Stimulation Therapy for Treating Chronic Pain Resulting from Diabetic Peripheral Neuropathy

The U.S. Food and Drug Administration (FDA) last month approved a rechargeable neurostimulator and a recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN). Medtronic is marketing the products as Intellis™ and Vanta™, respectively. DPN is a debilitating and progressive neurological disorder that affects approximately 30% of people with diabetes,...
Share

2021 Progress Report: Part 1

december 2021 cover Endocrine research remains at the forefront of medical breakthroughs, which has led to cutting-edge treatment options, therapies, and products. From remarkable new treatments for acromegaly, thyroid eye disease, hypoglycemia, and diabetes to new devices aimed at glucose monitoring in adults and children, a mail-in semen analysis kit, and much more, Endocrine News takes a closer...
Share

Evolution of Diabetes Management: The Patient-Provider Relationship, Accessing Resources, and Surmounting Obstacles

100_Years_of_Insulin_Logo During insulin’s first century, treatments and resources for people with diabetes have steadily progressed. So, too, have relationships between the patient and the provider. A recent Endocrine Society-hosted roundtable highlighted this vital connection and how it has evolved through the decades. Leonard Thompson was 14 years old in 1922, and he was dying of type...
Share

Rare But Devastating: Keeping Track of Acromegaly Cases

Since acromegaly is such a rare disorder, when an endocrinologist is presented with a potential case, the most accurate and complete data available would be a helpful tool. Endocrine News takes a closer look at how the Mexican Acromegaly Registry has helped endocrinologists address the issues patients with acromegaly face, both physically and financially.  ...
Share

Dosage Flexibility of Liquid Hypothyroidism Treatment Introduced for Patients and Clinicians

Americans diagnosed with hypothyroidism and their clinical providers now have access to greater dosage flexibility within levothyroxine therapy, with three new dosage strengths of levothyroxine sodium oral solution now available to treat hypothyroidism. IBSA Pharma markets the drug as Tirosint®-SOL. The unique new dosing options – 37.5, 44 and 62.5 micrograms – are a first...
Share

Continuous Glucose Monitor Developed to Integrate Data Directly into Electronic Health Record

HealthPartners Institute’s International Diabetes Center (IDC) recently developed and piloted a process for incorporating patients’ continuous glucose monitoring (CGM) data directly into the electronic health record (EHR), improving clinician access to glucose information. During a presentation at the American Diabetes Association’s 81st Scientific Sessions, IDC medical director Amy Criego, MD, described this process for integrating...